


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kaisa Health Group Holdings Limited
佳兆業健康集團控股有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 876)

POSITIVE PROFIT ALERT

This announcement is made by Kaisa Health Group Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company hereby informs the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment on the unaudited consolidated management accounts of the Group for the six months ended 30 June 2023 and information currently available to the Board, the Group is expected to record a profit attributable to the owners of the Company of not less than HK\$35 million for the six months ended 30 June 2023 which will be improved as compared to the net loss attributable to the owners of the Company in the amount of approximately HK\$97 million for the six months ended 30 June 2022.

Based on the information currently available, the turnaround from loss to profit for the six months ended 30 June 2023 was mainly due to a combination of factors as follows:

- (i) the gain on disposal of subsidiaries of approximately HK\$68 million which is mainly attributable to the fair value remeasurement of the interest retained by the Group recognised for the six months ended 30 June 2023;
- (ii) the fair value gain of financial liabilities at fair value through profit or loss of approximately HK\$0.87 million for the six months ended 30 June 2023 as compared with the corresponding period of a loss of approximately HK\$22 million in 2022;
- (iii) a significant decrease in impairment losses in the amount of approximately HK\$47 million, resulting from loss of control of the development project of Zhuhai Shili Lianjiang International Health City* (珠海十里蓮江國際健康城) for the health leisure business as at 30 June 2023; and

- (iv) the administrative expenses of approximately HK\$27 million for the six months ended 30 June 2023 as compared with the corresponding period of approximately HK\$47 million in 2022.

The Company is still in the process of finalising the interim results of the Group for the six months ended 30 June 2023. The information contained in this announcement is only based on the unaudited consolidated management accounts of the Group and information currently available to the Group, which is subject to finalisation and necessary adjustments and has neither been confirmed, or reviewed by the auditors of the Company, nor reviewed by the audit committee of the Company. Details of the financial results of the Group will be disclosed in the Group's interim results announcement for the six months ended 30 June 2023 which will be published in due course pursuant to the requirements of the Listing Rules. Shareholders and potential investors are advised to read the financial results announcement carefully when it is published.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board
Kaisa Health Group Holdings Limited
Kwok Ying Shing
Chairman

Hong Kong, 22 August 2023

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Kwok Ying Shing (Chairman), Mr. Luo Jun (Co-Vice Chairman), Mr. Wu Tianyu (Co-Vice Chairman) and Mr. Zhang Huagang, and three independent non-executive Directors, namely Dr. Liu Yanwen, Dr. Lyu Aiping and Ms. Li Zhiying.

** For identification proposes only*